This year’s Congress of the European Hematology Association (EHA) is cur­rent­ly being held in Stockholm. It started earlier this week and will run through Sunday, June 16.

A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster pre­sen­ta­tions.

This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and to­mor­row. A previous article covered the key findings that will be pre­sented during oral pre­sen­ta­tions.

The studies covered in this article are primarily ones …

The findings of a recent study suggest that the progression of both multiple myeloma and myeloma-related bone disease may be determined by measuring the levels of key proteins commonly found in bones. The study was published in the European Journal of Haematology.

Myeloma cells not only stimulate the formation of cells that break down bone, but also inhibit cells responsible for bone formation.  As a result, multiple myeloma patients have a high rate of bone disease characterized by bone pain and fractures.

Patients are typically treated with bisphosphonates to protect against …